Sowell Financial Services LLC Purchases New Holdings in DaVita Inc. (NYSE:DVA)

Sowell Financial Services LLC bought a new position in shares of DaVita Inc. (NYSE:DVA - Free Report) in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,378 shares of the company's stock, valued at approximately $364,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. United Capital Financial Advisors LLC grew its holdings in DaVita by 2.6% in the 4th quarter. United Capital Financial Advisors LLC now owns 2,416 shares of the company's stock valued at $361,000 after buying an additional 62 shares during the last quarter. Freedom Investment Management Inc. increased its position in DaVita by 3.6% during the fourth quarter. Freedom Investment Management Inc. now owns 1,790 shares of the company's stock worth $268,000 after acquiring an additional 62 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in DaVita by 2.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 3,551 shares of the company's stock valued at $531,000 after purchasing an additional 69 shares during the last quarter. UMB Bank n.a. boosted its holdings in DaVita by 65.5% in the 1st quarter. UMB Bank n.a. now owns 192 shares of the company's stock valued at $29,000 after purchasing an additional 76 shares during the period. Finally, Exchange Traded Concepts LLC grew its position in DaVita by 8.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 970 shares of the company's stock worth $148,000 after purchasing an additional 79 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company's stock.

Wall Street Analysts Forecast Growth

DVA has been the subject of several research reports. Wall Street Zen upgraded shares of DaVita from a "hold" rating to a "buy" rating in a research note on Friday, April 25th. Truist Financial cut their price target on DaVita from $170.00 to $164.00 and set a "hold" rating for the company in a report on Monday, May 19th. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $164.50.

DaVita Price Performance

DaVita stock traded up $4.56 during mid-day trading on Tuesday, hitting $140.90. 726,202 shares of the company were exchanged, compared to its average volume of 805,227. The company has a market capitalization of $10.64 billion, a PE ratio of 13.96, a price-to-earnings-growth ratio of 0.94 and a beta of 1.11. The business has a fifty day moving average of $139.55 and a 200 day moving average of $149.86. DaVita Inc. has a 1-year low of $131.76 and a 1-year high of $179.60. The company has a quick ratio of 1.20, a current ratio of 1.25 and a debt-to-equity ratio of 23.18.

DaVita (NYSE:DVA - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $2.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.25. The firm had revenue of $3.22 billion during the quarter, compared to the consensus estimate of $3.22 billion. DaVita had a net margin of 6.63% and a return on equity of 176.11%. The firm's quarterly revenue was up 5.0% on a year-over-year basis. During the same period last year, the firm posted $2.26 EPS. As a group, sell-side analysts expect that DaVita Inc. will post 10.76 earnings per share for the current year.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.